JP2006501149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501149A5 JP2006501149A5 JP2004500925A JP2004500925A JP2006501149A5 JP 2006501149 A5 JP2006501149 A5 JP 2006501149A5 JP 2004500925 A JP2004500925 A JP 2004500925A JP 2004500925 A JP2004500925 A JP 2004500925A JP 2006501149 A5 JP2006501149 A5 JP 2006501149A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- vitamin
- receptor
- derivative
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 102000035250 vitamin receptors Human genes 0.000 claims 15
- 108091005505 vitamin receptors Proteins 0.000 claims 15
- 210000004027 cells Anatomy 0.000 claims 11
- 229940088594 Vitamin Drugs 0.000 claims 10
- 235000013343 vitamin Nutrition 0.000 claims 10
- 239000011782 vitamin Substances 0.000 claims 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims 10
- 229930003231 vitamins Natural products 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 8
- 150000001768 cations Chemical class 0.000 claims 8
- 229940014144 Folate Drugs 0.000 claims 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical group C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 6
- 235000019152 folic acid Nutrition 0.000 claims 6
- 239000011724 folic acid Substances 0.000 claims 6
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 6
- 229910052713 technetium Inorganic materials 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 238000002059 diagnostic imaging Methods 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000003384 imaging method Methods 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000032895 transmembrane transport Effects 0.000 claims 4
- 102000006815 Folate receptors Human genes 0.000 claims 3
- 108020005243 Folate receptors Proteins 0.000 claims 3
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 3
- WUAPFZMCVAUBPE-UHFFFAOYSA-N Rhenium Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 3
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Chemical group OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 claims 3
- 229960002477 Riboflavin Drugs 0.000 claims 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Chemical group CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 3
- RMRCNWBMXRMIRW-WYVZQNDMSA-L Vitamin B12 Chemical group N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 3
- 235000020958 biotin Nutrition 0.000 claims 3
- 239000011616 biotin Substances 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 229910052733 gallium Inorganic materials 0.000 claims 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 3
- 229910052738 indium Inorganic materials 0.000 claims 3
- 229910052702 rhenium Inorganic materials 0.000 claims 3
- 235000019192 riboflavin Nutrition 0.000 claims 3
- 239000002151 riboflavin Chemical group 0.000 claims 3
- 235000019157 thiamine Nutrition 0.000 claims 3
- 239000011721 thiamine Chemical group 0.000 claims 3
- 229960003495 thiamine Drugs 0.000 claims 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical group CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 3
- 230000037177 Biodistribution Effects 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 1
Claims (22)
- Vが、葉酸塩、リボフラビン、チアミン、ビタミンB12、および、ビオチンからなる群から選択されるビタミン、または、そのビタミンレセプターに結合するその誘導体もしくはそのアナログであることを特徴とする請求項1に記載の化合物。
- 前記放射性核種が、ガリウム、インジウム、銅、テクネチウムおよびレニウムの同位元素からなる群から選択されることを特徴とする請求項1または2に記載の化合物。
- 前記放射性核種が、テクネチウムの同位元素であることを特徴とする、請求項3に記載の化合物。
- Vが、葉酸塩、または、葉酸レセプターに結合するそのアナログもしくはその誘導体であることを特徴とする、請求項1〜4のいずれかに記載の化合物。
- 前記化合物中のVが、葉酸塩、リボフラビン、チアミン、ビタミンB12およびビオチンからなる群から選択されるビタミン、または、ビタミンレセプターに結合するその誘導体もしくはそのアナログであることを特徴とする請求項6に記載の組成物。
- 前記化合物中の前記放射性核種が、ガリウム、インジウム、銅、テクネチウムおよびレニウムの同位元素からなる群から選択されることを特徴とする請求項6または7に記載の組成物。
- 前記化合物中の前記放射性核種が、テクネチウムの同位元素であることを特徴とする請求項8に記載の組成物。
- 非経口投与に適応した請求項6〜9のいずれかに記載の組成物。
- Vが、葉酸塩、または、葉酸レセプターに結合するそのアナログもしくはその誘導体であることを特徴とする請求項6〜10のいずれかに記載の化合物。
- 前記化合物中のVが、葉酸塩、リボフラビン、チアミン、ビタミンB12およびビオチンからなる群から選択されるビタミン、または、ビタミンレセプターに結合するその誘導体もしくはそのアナログであることを特徴とする請求項12または13に記載の使用方法。
- 前記化合物中の前記放射性核種が、ガリウム、インジウム、銅、テクネチウムおよびレニウムの同位元素からなる群から選択されることを特徴とする請求項12〜14のいずれかに記載の使用方法。
- 前記化合物中の前記放射性核種が、テクネチウムの同位元素であることを特徴とする、請求項15に記載の使用方法。
- 前記組成物が、動物に対して非経口的に投与されることを特徴とする請求項12〜16のいずれかに記載の使用方法。
- Vが、葉酸塩、または、葉酸レセプターに結合するそのアナログまたはその誘導体であることを特徴とする請求項12〜17のいずれかに記載の使用方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37857102P | 2002-05-06 | 2002-05-06 | |
US60/378,571 | 2002-05-06 | ||
PCT/US2003/014379 WO2003092742A1 (en) | 2002-05-06 | 2003-05-06 | Vitamin-targeted imaging agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010161087A Division JP4801786B6 (ja) | 2002-05-06 | 2010-07-15 | ビタミンを標的とした造影剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006501149A JP2006501149A (ja) | 2006-01-12 |
JP2006501149A5 true JP2006501149A5 (ja) | 2006-06-15 |
JP4801348B2 JP4801348B2 (ja) | 2011-10-26 |
Family
ID=29401611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004500925A Expired - Fee Related JP4801348B2 (ja) | 2002-05-06 | 2003-05-06 | ビタミンを標的とした造影剤 |
Country Status (19)
Country | Link |
---|---|
US (5) | US7128893B2 (ja) |
EP (4) | EP2260875B1 (ja) |
JP (1) | JP4801348B2 (ja) |
KR (1) | KR100978418B1 (ja) |
CN (2) | CN100528241C (ja) |
AT (1) | ATE448799T1 (ja) |
AU (1) | AU2003239383C1 (ja) |
CA (1) | CA2484345C (ja) |
CY (1) | CY1114733T1 (ja) |
DE (1) | DE60330135D1 (ja) |
DK (3) | DK2151250T3 (ja) |
ES (4) | ES2438008T3 (ja) |
HK (1) | HK1141440A1 (ja) |
IL (1) | IL164811A (ja) |
NZ (1) | NZ536467A (ja) |
PT (2) | PT2260875E (ja) |
SI (2) | SI2260875T1 (ja) |
WO (1) | WO2003092742A1 (ja) |
ZA (1) | ZA200408664B (ja) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
EP1390077B1 (en) | 2001-05-02 | 2014-07-16 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
US8043603B2 (en) * | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
PT2260875E (pt) | 2002-05-06 | 2014-06-25 | Endocyte Inc | Agentes de imagiologia direcionados para recetor de folato |
WO2003097647A1 (en) * | 2002-05-15 | 2003-11-27 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
CA2527196C (en) * | 2003-05-30 | 2012-10-16 | Purdue Research Foundation | Diagnostic method for atherosclerosis |
JP5149620B2 (ja) | 2004-07-23 | 2013-02-20 | エンドサイト,インコーポレイテッド | 2価リンカーおよびその結合体 |
US7977500B2 (en) * | 2004-11-10 | 2011-07-12 | University Of South Florida | Platinum complexes for targeted drug delivery |
WO2006071754A2 (en) * | 2004-12-23 | 2006-07-06 | Purdue Research Foundation | Positron emission tomography imaging method |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
EP1904183B1 (en) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
EP2382995A3 (en) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
AU2006279304A1 (en) | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
EP1940473A2 (en) | 2005-09-23 | 2008-07-09 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
US8685752B2 (en) | 2006-11-03 | 2014-04-01 | Purdue Research Foundation | Ex vivo flow cytometry method and device |
EP2567711A3 (en) * | 2007-02-07 | 2013-05-01 | Purdue Research Foundation | Positron emission tomography imaging method |
EP2604283A1 (en) * | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008112873A2 (en) | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
EP2146995A1 (en) * | 2007-04-11 | 2010-01-27 | Merck Eprova AG | Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy |
CN107573347A (zh) | 2007-04-11 | 2018-01-12 | 默克和西伊公司 | 18f‑标记的叶酸 |
CA2688308A1 (en) * | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
CN104383553A (zh) | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
HUE047200T2 (hu) | 2007-08-17 | 2020-04-28 | Purdue Research Foundation | PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei |
EP2209374B1 (en) | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysins and processes for preparing |
US20100272675A1 (en) * | 2007-11-15 | 2010-10-28 | Endocyte, Inc. | Method of administering conjugates |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US8426398B2 (en) | 2009-01-13 | 2013-04-23 | Emory University | Conjugates of noscapine and folic acid and their use in treating cancer |
CA2753975C (en) | 2009-03-02 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
WO2010102238A1 (en) * | 2009-03-05 | 2010-09-10 | Purdue Research Foundation | Method for early imaging of atherosclerosis |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
AU2011237729B2 (en) | 2010-04-05 | 2014-04-03 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
WO2011133868A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Conformationally restricted dinucleotide monomers and oligonucleotides |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
EP2683410A2 (en) | 2011-03-08 | 2014-01-15 | Access Pharmaceuticals, Inc. | Targeted nanocarrier systems for delivery of actives across biological membranes |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
WO2013024035A1 (en) | 2011-08-17 | 2013-02-21 | Merck & Cie | Folate conjugates of albumin-binding entities |
US9884123B2 (en) | 2012-01-03 | 2018-02-06 | Invictus Oncology Pvt. Ltd. | Ligand-targeted molecules and methods thereof |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
WO2013130776A1 (en) * | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CA2880001A1 (en) * | 2012-07-25 | 2014-01-30 | Emory University | Imaging and therapeutic methods for treating parathyroid tumors |
BR112015008365A2 (pt) | 2012-10-16 | 2017-07-04 | Endocyte Inc | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente |
EP3901280A1 (en) | 2012-10-17 | 2021-10-27 | Spatial Transcriptomics AB | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
KR101551232B1 (ko) | 2012-10-26 | 2015-09-10 | 한국원자력연구원 | N3s1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물 |
JP6892218B2 (ja) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 薬物送達結合体およびpsma発現細胞によって引き起こされる疾患の治療方法 |
WO2014150943A1 (en) * | 2013-03-15 | 2014-09-25 | Purdue Research Foundation | Asthma imaging and therapy |
EP4234716A3 (en) | 2013-06-25 | 2023-12-06 | Prognosys Biosciences, Inc. | Methods for determining spatial patterns of biological targets in a sample |
EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
CN105849568B (zh) * | 2013-11-14 | 2018-05-04 | 恩多塞特公司 | 用于正电子发射断层术的化合物 |
US11162937B2 (en) | 2013-11-19 | 2021-11-02 | Purdue Research Foundation | Patient selection method for inflammation |
CA2944401A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
US9850183B2 (en) | 2014-06-27 | 2017-12-26 | Reiley Pharmaceuticals, Inc. | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging |
US20160166679A1 (en) * | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Reversir(商標)化合物 |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3242688B1 (en) | 2015-01-09 | 2020-01-29 | Reiley Pharmaceuticals, Inc. | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers |
CA2982146A1 (en) | 2015-04-10 | 2016-10-13 | Spatial Transcriptomics Ab | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
EP3324980B1 (en) | 2015-07-17 | 2021-11-10 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
EP3334466B1 (en) | 2015-08-14 | 2020-05-13 | Endocyte, Inc. | Method of imaging with a chelating compound |
CN108431232B (zh) | 2015-12-04 | 2022-10-14 | 10X 基因组学有限公司 | 用于核酸分析的方法和组合物 |
EP3429637A4 (en) | 2016-03-16 | 2020-03-11 | Endocyte, Inc. | CONJUGATES OF CARBONIC ANHYDRASE IX INHIBITORS AND USES THEREOF |
JP7027325B2 (ja) * | 2016-03-16 | 2022-03-01 | パーデュー・リサーチ・ファウンデイション | 炭酸無水酵素ixを標的とする薬剤および方法 |
US20170296679A1 (en) | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
US11524082B2 (en) | 2017-08-22 | 2022-12-13 | Purdue Research Foundation | FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers |
KR20210018267A (ko) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
CA3114396A1 (en) | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
AU2020279101A1 (en) | 2019-05-17 | 2021-11-18 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
WO2021086982A2 (en) | 2019-10-28 | 2021-05-06 | Beckman Coulter, Inc. | Compounds for the identification of microbial classes and uses thereof |
CN114945669A (zh) | 2019-11-06 | 2022-08-26 | 阿尔尼拉姆医药品有限公司 | 肝外递送 |
WO2021092145A1 (en) | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases |
EP4162074B1 (en) | 2020-06-08 | 2024-04-24 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
US11981960B1 (en) | 2020-07-06 | 2024-05-14 | 10X Genomics, Inc. | Spatial analysis utilizing degradable hydrogels |
WO2022011214A1 (en) | 2020-07-10 | 2022-01-13 | Alnylam Pharmaceuticals, Inc. | Circular sirnas |
JP2023543335A (ja) | 2020-10-30 | 2023-10-13 | スピア、トッド | オリゴヌクレオチドベースの治療剤およびその使用 |
JP2024501857A (ja) | 2020-12-31 | 2024-01-16 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ |
EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
US20240165250A1 (en) * | 2021-01-08 | 2024-05-23 | Lycia Therapeutics, Inc. | Bifunctional Folate Receptor Binding Compounds |
WO2022256503A1 (en) | 2021-06-03 | 2022-12-08 | 10X Genomics, Inc. | Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
AU2022314619A1 (en) | 2021-07-21 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Metabolic disorder-associated target gene irna compositions and methods of use thereof |
AU2022364838A1 (en) | 2021-10-15 | 2024-04-11 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2816110A (en) * | 1956-11-23 | 1957-12-10 | Merck & Co Inc | Methods for the production of substituted pteridines |
US5140104A (en) * | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
US5175343A (en) * | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
NZ217821A (en) | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5053493A (en) * | 1987-04-02 | 1991-10-01 | Centocor Cardiovascular Imaging Partners, L.P. | Method for labeling antibodies with a metal ion |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US7238340B1 (en) * | 1991-11-27 | 2007-07-03 | Cis Bio International | Monoamine, diamide, thiol-containing metal chelating agents |
EP0570493B1 (en) | 1991-02-08 | 2000-01-05 | Diatide, Inc. | TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING |
US6335434B1 (en) * | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5159079A (en) * | 1991-12-20 | 1992-10-27 | Eli Lilly And Company | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids |
US6022966A (en) | 1993-11-22 | 2000-02-08 | Neorx Corporation | Pretargeting methods and compounds |
DE4311021A1 (de) * | 1993-03-31 | 1994-10-27 | Diagnostikforschung Inst | Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel |
DE4310999C2 (de) * | 1993-03-31 | 1996-07-18 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4311022C2 (de) * | 1993-03-31 | 1996-07-11 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4311023C2 (de) * | 1993-03-31 | 1996-05-02 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4425781A1 (de) * | 1994-07-14 | 1996-01-18 | Schering Ag | Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel |
US6083480A (en) * | 1997-05-01 | 2000-07-04 | Diatide, Inc. | Calcitonin receptor binding reagents |
US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
US6323313B1 (en) * | 1999-06-01 | 2001-11-27 | The University Of Washington | Annexin derivative with endogenous chelation sites |
DK1286704T3 (da) * | 2000-06-02 | 2014-09-22 | Univ Texas | Ethylendicystein (EC)-glucose analoge konjugater |
EP1390077B1 (en) * | 2001-05-02 | 2014-07-16 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
PT2260875E (pt) | 2002-05-06 | 2014-06-25 | Endocyte Inc | Agentes de imagiologia direcionados para recetor de folato |
DK1592457T3 (da) * | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
-
2003
- 2003-05-06 PT PT101795086T patent/PT2260875E/pt unknown
- 2003-05-06 SI SI200332355T patent/SI2260875T1/sl unknown
- 2003-05-06 EP EP10179508.6A patent/EP2260875B1/en not_active Expired - Lifetime
- 2003-05-06 AT AT03733967T patent/ATE448799T1/de not_active IP Right Cessation
- 2003-05-06 CA CA2484345A patent/CA2484345C/en not_active Expired - Fee Related
- 2003-05-06 PT PT91715037T patent/PT2151250E/pt unknown
- 2003-05-06 DK DK09171503.7T patent/DK2151250T3/da active
- 2003-05-06 CN CNB038146835A patent/CN100528241C/zh not_active Expired - Fee Related
- 2003-05-06 CN CN200910151274XA patent/CN101648028B/zh not_active Expired - Fee Related
- 2003-05-06 DK DK10179448.5T patent/DK2258401T3/da active
- 2003-05-06 JP JP2004500925A patent/JP4801348B2/ja not_active Expired - Fee Related
- 2003-05-06 EP EP03733967A patent/EP1501551B1/en not_active Expired - Lifetime
- 2003-05-06 DK DK10179508.6T patent/DK2260875T3/da active
- 2003-05-06 ES ES09171503.7T patent/ES2438008T3/es not_active Expired - Lifetime
- 2003-05-06 ES ES10179508.6T patent/ES2472423T3/es not_active Expired - Lifetime
- 2003-05-06 EP EP09171503.7A patent/EP2151250B1/en not_active Expired - Lifetime
- 2003-05-06 SI SI200332331T patent/SI2151250T1/sl unknown
- 2003-05-06 DE DE60330135T patent/DE60330135D1/de not_active Expired - Lifetime
- 2003-05-06 US US10/430,519 patent/US7128893B2/en not_active Expired - Lifetime
- 2003-05-06 WO PCT/US2003/014379 patent/WO2003092742A1/en active Application Filing
- 2003-05-06 AU AU2003239383A patent/AU2003239383C1/en not_active Ceased
- 2003-05-06 EP EP10179448.5A patent/EP2258401B1/en not_active Expired - Lifetime
- 2003-05-06 ES ES10179448.5T patent/ES2500922T3/es not_active Expired - Lifetime
- 2003-05-06 NZ NZ536467A patent/NZ536467A/en not_active IP Right Cessation
- 2003-05-06 KR KR1020047017608A patent/KR100978418B1/ko active IP Right Grant
- 2003-05-06 ES ES03733967T patent/ES2336780T3/es not_active Expired - Lifetime
-
2004
- 2004-10-25 IL IL164811A patent/IL164811A/en active IP Right Grant
- 2004-10-26 ZA ZA200408664A patent/ZA200408664B/en unknown
-
2006
- 2006-10-11 US US11/546,099 patent/US7862798B2/en not_active Expired - Fee Related
-
2009
- 2009-09-11 US US12/558,163 patent/US8313728B2/en not_active Expired - Lifetime
-
2010
- 2010-08-16 HK HK10107801.2A patent/HK1141440A1/xx not_active IP Right Cessation
-
2012
- 2012-10-18 US US13/654,527 patent/US8865126B2/en not_active Expired - Fee Related
-
2013
- 2013-03-11 US US13/793,624 patent/US8834842B2/en not_active Expired - Fee Related
- 2013-12-27 CY CY20131101164T patent/CY1114733T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006501149A5 (ja) | ||
JP6749249B2 (ja) | Psmaを標的としたイメージング及び放射線治療のための金属/放射性金属標識psma阻害剤 | |
EP1501551B1 (en) | Folate-receptor targeted imaging agents | |
EP2567711A3 (en) | Positron emission tomography imaging method | |
JP2007530577A5 (ja) | ||
Chefer et al. | In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I] iodo-A-85380 using single photon emission computed tomography | |
WO2006044174A3 (en) | Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor | |
CN110678227B (zh) | 使用与放射性同位素螯合的奥曲肽衍生物治疗过表达生长抑素受体的癌细胞 | |
SG152254A1 (en) | Contrast agents for myocardial perfusion imaging | |
SG149895A1 (en) | Contrast agents for myocardial perfusion imaging | |
BRPI0512058A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
JP2013528180A5 (ja) | ||
ATE383850T1 (de) | Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung | |
JP2005531564A5 (ja) | ||
AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
WO2006110884A8 (en) | 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists | |
JP2007500730A5 (ja) | ||
BRPI0413676A (pt) | composto, e, composição farmacêutica | |
WO2003093412A3 (en) | Tumor imaging compounds | |
JP2007515467A5 (ja) | ||
JP2005523941A5 (ja) | ||
JP2014500268A5 (ja) | ||
JP2004529117A5 (ja) | ||
PT2366396E (pt) | Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina |